AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2016
Nov 22, 2016
31920_dirs_2016-11-22_3c906215-b224-4a89-938d-e338b5e74165.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FLAMEL TECHNOLOGIES SA (FLML)
CIK: 0001012477
Period of Report: 2016-11-21
Reporting Person: ANDERSON MICHAEL S (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-11-21 | ADSs | P | 2000 | $10.637 | Acquired | 193250 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $6.93 | 2022-03-08 | ADSs (275000) | 275000 | Direct |
| Stock Option (right to buy) | $4.07 | 2023-02-01 | ADSs (80500) | 80500 | Direct |
| Stock Option (right to buy) | $16.3 | 2024-12-11 | ADSs (200000) | 200000 | Direct |
| Stock Option (right to buy) | $14.35 | 2025-12-10 | ADSs (200000) | 200000 | Direct |
Footnotes
F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.625 to $10.64, inclusive. The reporting person undertakes to provide to Flamel Technologies S.A., any security holder of Flamel Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
F3: Includes (a) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date, provided that the reporting person continues to be employed by the issuer or an affiliate thereof on the second anniversary of the grant date; and (b) 50,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
F4: Options became exercisable in four equal amounts over the first four anniversaries after the 03/08/2012 grant date.
F5: Options become exercisable as to 20,125 ADSs on each of the first four anniversaries after the 02/01/2013 grant date.
F6: Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
F7: Options become exercisable as to 50,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.